thank Puma million of million. in million million, $XX.X reported total for Mariann, $X net $XX.X $XX.X our Total XXXX the NERLYNX revenue license $X.X reported sales quarter XXXX of the revenue you, net sales from represented fourth all sales of and of of call of $XX.X quarter X.X% and million. joining consisted Thank royalty Net you product revenue third the of of revenue XXXX. quarter in fourth increase million of the for today. a of Today in
provide their licensing year Latin amplified extended our of that the with one trastuzumab-based of quarter than adjuvant announced received less over-expressed with Pharma highlights begin will we some America, review completed cancer adult highlights Maximo NERLYNX' Nougues HERX with regulatory statements partner U.S. Pint treatment fourth the adjuvant approval for therapy first September, will a early-stage in Argentina in receptor ago. of the positive, who and for of XXXX. on financial the commercial In of quarter components key in of follow our the I then for more activities of hormone and breast patients details the NERLYNX
sales licensing be In receiving Hong those commercialized. once those we in the from territories Kong. approval of According they partner that received Pharmaceuticals of in in of market terms Puma will November, Greater are entities, NERLYNX China, our CANbridge announced the to with licensing royalties agreements the both
and the also United decisions announcing States countries partners, collaboration with Europe outside of neratinib regulatory In on our in XXXX. throughout licensed additional anticipate we additional
ASCO also June. of neratinib accessible known metastatic Society website. the in presentation and are trial from in American of Annual on of As breast the NALA III in investors quarter the results Puma's Oncology HERX-positive of Clinical the of cancer webcast the Meeting second Phase as our at XXXX, aware page is we presented third-line events A trial copy
Based results June in trial, sNDA of for sNDA application filed was accepted XXXX. Puma September the XXXX. of The our the neratinib PDUFA or in new for by metastatic drug supplemental a third-line XXXX of April NALA FDA anticipated cancer of date HERX-positive on and breast the is the treatment
We on will continue investors as it this regulatory to update progress our with progresses.
In XXXX, treatment metastases. drug neratinib breast granted FDA patients September cancer to addition, in with orphan the of the brain designation for
cancers referred aware, trial. As trial the an has SUMMIT neratinib in Puma also investors basket to are of ongoing as HERX-mutated
On earnings neratinib plus our positive a that will SUMMIT trastuzumab, alone, in the seven or if arm further for based plus responds study patients such enroll recent will fulvestrant ER Stage combination call, enrollment. to will closed X the Puma HERX-negative plus during amended have arm of of and receive patient patients a arm Each meeting either the modifying trastuzumab. fulvestrant the that breast that given cancer be no mutation quarter our randomized on we trial who fulvestrant is be third with announced FDA, HERX initially
less expanded will that If one in or closed further enrollment. to four XX enrolled. then patients respond be up patients arm cohort be arm patients will patients. the the four to the in will and than than If to expanded the more expanded further stage first If will respond be patients arm be more respond
amendment three sites submitted the the that the We to that participating begin are month. the to amendment approved an be study. The arms and in been will SUMMIT clinical at next enrollment protocol to will the anticipate has sites these
anticipates HERX the this the negative accelerated meeting to to place we pre-NDA through of mutation. between neratinib potential that has continue will of in with a to Simon take results of after a the quarter sometime We XXXX the Puma that FDA XXXX. fourth the HERX receive initial quarter schedule approval order the from for trial plan discuss cancer breast meeting second positive, ER in two-stage
the and During efficient goal with to lab patients in also a by biopsy with with our SUMMIT. to initiated of HERX high cancer current HERX clinical breast low-cost known we in can test liquid discussed for as who cancer way developed patients screening This for cervical Puma is trial a earnings represents run be enrolled quarter a call, HER-Seq The NGS-based proprietary HERX using then our screen successfully third and was mutation HER-Seq. also test throughput assay validated mutations. a trial mutations, central screen trial
the biopsy The a found trial Puma. trial with was in taken mutation, retested the to have initiated not the are developed exercise same six December three XXXX. does months If HERX patient HERX blood they breast patients see, a to are In later the are is the mutation trial cancer, HERX metastatic eligible a to samples is the patient and is or of to mutation, if SUMMIT by with the cervical streamed from have liquid referred enroll. patient again. is If to test and performed proprietary patient cancer
to is cervical calls. of on SUMMIT We HER-Seq to to participating to The than accelerated are for look enough being other the expanded and should the identify HER-Seq investors and X,XXX progress more SUMMIT. and screen cancer opened cancer filing. in currently process patients trial patients X,XXX which trial sites to sites The is future XX in HER-Seq at continuing is breast approximately with forward patients support currently conference that NDA potential the of on update approval goal the the SUMMIT
in claims XXXXXXXX its for claim of issued the for these U.S. United related Also XXXX and/or issue XXXX. months were lung methods of for and the forward methods The cell A U.S. application non-small in pending TXXXM in of fees of updating of erlotinib-resistant States continuation also we was mutation gefitinib non-small cancer. coming January look cell XXXXXXXX and Office in both regarding of U.S. treating paid XXXX, EGFR. regarding and issued in lung treating February by notice a progresses. for Trademark patents erlotinib-resistant was it to application for the this a having Patent allowance notice investors gefitinib treatment these as January issue on anticipate that will cancer We applications allowance
NERLYNX. now will our U.S. progress I for review commercialization
First will reminder I a forward-looking be that, of statements. making just all,
of as to and specialty refer recall, two our that our in-office in our quarter. approximately may third the the the XX% In to approximately the you quarter, specialty XX% in distribution in or distribution quarter. channel sold NERLYNX distribution pharmacy specialty similar bottles have As provide We bottles to the channel, is sold we the patients. fourth channel. This channel these channels represented
the number you the now total the results. but prescribers XXXX. Later an approximately the of During in specialty we number for noted also with to prescriptions compared NERLYNX the increase quarter financial third NERLYNX will The review the physicians call in quarter prescribers provide fourth the the pharmacy sales total I number will Maximo results, NERLYNX. in in fourth of X.X% in quarter, new network writing of current of full the XXXX of increased
slide the net since approval. On FDA X, shows of it sales quarterly NERLYNX
the was our sales As net million million fourth a $XX.X in increase third revenue I the previously from the in quarter, reported $XX.X XXXX. in quarter of stated, net sales product X.X%
at XXXX, the and with data month during diarrhea tolerability. we escalation three our from control the Annual using Breast Clinical San a the at shown Society the and NERLYNX Oncology trial, presented American During of dose grade improved associated Meeting of Cancer reduces Symposium, Antonio first NERLYNX that treatment,
trial. in the percentage technique which physicians the indicative Since from lower that we the starting we have presented, the of is using data physicians believe new using an increasing NERLYNX, control dose was noticed data escalation of are a described of dose
can slide, that the to dose from XX.X% the prescriptions increased QX appear QX. in see percent you from escalation be new As in technique to this using of XX.X%
neratinib six the of Slide bottles sold quarter. shows by
inventory. X% February first approximately to in an during QX quarter, pharmacies the down bottles that January there approximately in continue have notice throughout fourth we this number one purchased increase quarter. sold of in approximate pharmacies believe sequentially and inventory excess which the increased will inventory of specialty in by We and X,XXX the specialty was week to drawing been from expect the was The in You by this X,XXX QX that QX.
with of starting declined due the greatest the that and -- the of in of Year's occurred patient XX.X% occur holidays third and avoid patients believe more NERLYNX taking the quarter to in XXXX. The NRX that decline the first holidays. which effects drug. frequency until November We in order New third and side quarter from Thanksgiving, tend GI from Christmas this patients fourth is after the during NRX while quarter quarter around X.X% month may TRX starting the the XXXX, experiencing December have mostly specifically to the the fourth so or of declined the been in to delaying in months NERLYNX, NERLYNX the
in of number large these may believe signing the fourth from may who holidays. until a NERLYNX continue average up pharmacy signing up be increase new XX% this number increase see We delayed patients quarter patients, for in of which who to the specialty closely. January, the do the after in of quarter pharmacy XXXX. starting for the know indeed number The did this signed patients throughout in from if new We we the patients increase month specialty due have will the was January not of are fourth we monitoring per but QX, a up
in the the lighter their patient pharmacy in to signing new two As discussed number trending can early their have when it in sharp although early is we to Puma which patients a NRX NRX. the January, in and patients, specialty approximately the sign two for into January expected, been up for weeks prescriptions pharmacy, signing patients bolus but increase investors due actually than these prior the patients there's since of for pharmacy did in out start receive these late and up earnings for prescription, to takes up prescription and specialty for approximately February, this up take getting specialty to calls, of see Therefore, with believe new receive for we actually filled. January the started it their weeks
refills a saw in NERLYNX as patients use to quarter. the slight due We believe dose bottles approximately the that new of may an starting escalation at number also in less in dose. initial these in expected to have previous decline in the patients for sold we the lower mentioned XX% in January lead the started technique increase January, QX the slide patients this In that of a
are bottles we control in in to in that rate although it an However, the achieve. decline the decreases we've study, overall per lead to able if what patient discontinuation dose initially a seen indeed potential we the escalation to this anticipate revenue the to leads will increase similar that sold,
after patients six of We continuing for an recently and take drug six to percent performed the those of the standard did early, patients patients future. continue will increase trend an in months the This the data lower NERLYNX we those but still were indeed encouraging who analysis monitor to NERLYNX months who percent this taking analysis taking show of the who after started dose. NERLYNX dose compared and is to a the at at in started
We calls. of trends sales will all to forward earnings in monitor to and future this to these reporting continue look investors
committed the across also regulatory partnerships companies to are world making We available and commercial throughout the with and that region. formed have in who patients have NERLYNX to world expertise
XXXX, in approved countries and the as on NERLYNX several was outside States and the United slide. seen -- During is Europe
the the During to countries our and quarter. XXXX, America and we Europe, is NERLYNX Kingdom this as China the NERLYNX fourth and several the including approved South In partner during look countries America slide. additional other Fabre Pierre in to Austria in Germany, seen forward for potential launched United year, in be Latin on
launch We future. although it to that have we been in XXXX XX our initial investors it updating in European Europe as We the early has NERLYNX and with in forward of initial launch is been launch will recognize look the anticipate approximately the throughout the countries in on drug Pierre their projections, Fabre very to we additional exceeding eight launch. still pleased
now our turn for over call Nougues the results. of will review to Maximo I a financial
